ArticleJournal for immunotherapy of cancer2023
CD8
Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Cytokine profiles as predictive biomarkers for treatment outcomes in advanced gastric cancer patients undergoing PD-1 blockade immunochemotherapy: a meta-analysis.Clinical and experimental medicine · 2025Pooled it
- Why CD4+ T cells matter in adoptive cell therapy for solid cancers.Immuno-oncology technology · 2026Review
- Integrative multi-omics and network toxicology reveal candidate molecular targets of deoxynivalenol in melanoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Depletion of CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Impact of blinatumomab and inotuzumab exposure on apheresis composition for CAR T in patients with B-cell acute lymphoblastic leukemia.Cytotherapy · 2026Article
- Article
- Naïve CD4Nature communications · 2026Article
- Review
- PD-1: CD28 chimeric receptors enhance phenotypic and functional features of T cell subsets.Research in pharmaceutical sciences · 2026Article
- Are we there yet? The road to faster and more efficient CAR T cell manufacturing.Journal of biological engineering · 2026Review
- Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases.Precision clinical medicine · 2026Review
- Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia.Journal of translational medicine · 2026Article
- Data-driven computational modeling of CAR-T cell function.Frontiers in immunology · 2026Article
- Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies.Frontiers in immunology · 2026Review
- CAR-T manufacturing reduces heterogeneity between CIDP and multiple myeloma patient-derived T cells.Theranostics · 2026Article
- Precision sniper for solid tumors: CAR-NK cell therapy.Cancer immunology, immunotherapy : CII · 2025Review
- Chimeric antigen receptor therapies: Development, design, and implementation.The Journal of allergy and clinical immunology · 2025Review
- Progress of immune senescence in multiple myeloma treatment resistance.Discover oncology · 2025Review
- Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma.Blood neoplasia · 2025Article
- Challenges in the preclinical design and assessment of CAR-T cells.Frontiers in immunology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 1 institution in 4 countries.
Funding
Abstract
backgroundCell culture conditions during manufacturing can impact the clinical efficacy of chimeric antigen receptor (CAR) T cell products. Production methods have not been standardized because the optimal approach remains unknown. Separate CD4
methodsWe generated CAR T cells either as separate CD4
resultsWe found that the coculture of CD8
conclusionsOur data indicate that CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.